ReviewAnnals of medicine2026
Insulin like growth factor - insulin like growth factor binding protein family in osteoporosis: mechanistic and clinical insights.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe imbalance between osteoblasts and osteoclasts is central to osteoporosis.Insulin like growth factor (IGF) has protective effects on bone. As an IGF-binding protein, the role of IGFBP in bone has also begun to come into the public's view. IGFBP not only serves as an IGF reservoir but also acts independently, interacting with other ligands to regulate cell proliferation and differentiation. Due to the complexity of the molecular network of IGF-IGFBP, the specific mechanism by which IGF-IGFBP affects bone is still unknown. This review introduces the IGF-IGFBP network and its roles in osteogenesis and osteoclast differentiation, and explores its potential as a novel therapeutic target for osteoporosis.
methodRelevant studies were identified in PubMed and Web of Science using the keywords 'IGFBP', 'Bone', and 'Osteoporosis', followed by a comprehensive review of the literature.
resultsIGF-IGFBP regulates bone metabolism by modulating the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteogenic and adipogenic lineages, as well as the differentiation process of osteoclasts. Current studies mainly focuson osteogenic differentiation, while research on adipogenic and osteoclastogenic differentiationis limited. Some IGFBP molecules show inhibitory effects in osteogenesis, but their detailed molecular mechanisms are not fully elucidated.
conclusionThe IGF-IGFBP family influences bone metabolism through multiple biological pathways. However, the precise molecular mechanisms by which this system regulates bone metabolism remain incompletely understood. Future studies are needed to systematically elucidate its functional networks and pathophysiological significance in bone metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.